95th Congress [ HOUSE OF REPRESENTATI VES 
2d Session J 
Rept. 95- 
1005 Part 2 
RECOMBINANT DNA ACT 
April 21, 1978. — Ordered to be printed 
Mr. Teague, from the Committee on Science and Technology, 
submitted the following 
REPORT 
together with 
DISSENTING VIEWS 
[To accompany H.R. 11192] 
[Including cost estimate of the Congressional Budget Office] 
The Committee on Science and Technology, to whom was referred 
the bill (H.R. 11192) to extend for 2 years the scope of the contain- 
ment requirements and the requirements of the experimental guide- 
lines of the National Institutes of Health respecting recombinant DNA 
research to include all public and private recombinant DNA activi- 
ties and to provide for a study respecting research and technology 
involving genetic manipulation, having considered the same, report 
favorably thereon with amendments and recommend that the bill as 
amended do pass. 
The amendments are as follows (page and line references are to the 
bill as reported by the Committee on Science and Technology) : 
Page 2, line 17, strike out “is” and insert in lieu thereof “may be”. 
Page 7, line 7, strike out “may” and insert in lieu thereof “shall”. 
Page 7, line 10, after “(a)(1)” insert the following : 
, as well as provisions giving due consideration to the need for 
protection against improper or unwarranted disclosure of 
privileged, confidential, or proprietary information, trade 
secrets, and information held under patent rights 
Page 8, line 22, strike out “shall” and insert in lieu thereof “may”. 
Page 17, lines 1 and 2, insert the following new subsection : 
(c) No part of this title shall remain in effect beyond the end of the 
period specified in section 102(a) (1). 
Page 17, line 6, after “established” insert “, within the Department 
of Health, Education, and Welfare,”. 
(l) 
[Appendix B — 189] 
